Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 5 | 2021 | 318 | 1.180 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 2384 | 1.150 |
Why?
|
| Radiation Oncology | 1 | 2022 | 124 | 0.630 |
Why?
|
| Leukopenia | 1 | 2020 | 65 | 0.630 |
Why?
|
| Melanoma | 1 | 2023 | 495 | 0.600 |
Why?
|
| Liver | 4 | 2016 | 1231 | 0.570 |
Why?
|
| Radiation Injuries | 3 | 2016 | 159 | 0.550 |
Why?
|
| Neoplasms | 4 | 2021 | 3242 | 0.540 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 848 | 0.540 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 345 | 0.520 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 790 | 0.520 |
Why?
|
| Cholangiocarcinoma | 2 | 2016 | 80 | 0.450 |
Why?
|
| Bile Duct Neoplasms | 2 | 2016 | 91 | 0.450 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2015 | 68 | 0.440 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 315 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1144 | 0.360 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2016 | 426 | 0.350 |
Why?
|
| Spindle Apparatus | 1 | 2008 | 66 | 0.280 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 120 | 0.280 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2008 | 184 | 0.260 |
Why?
|
| Humans | 22 | 2023 | 95992 | 0.260 |
Why?
|
| Radiotherapy Dosage | 4 | 2021 | 476 | 0.250 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 412 | 0.240 |
Why?
|
| Databases, Factual | 2 | 2021 | 1014 | 0.230 |
Why?
|
| Repressor Proteins | 1 | 2008 | 447 | 0.230 |
Why?
|
| Papilloma | 1 | 2023 | 23 | 0.200 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 89 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 117 | 0.180 |
Why?
|
| Uncertainty | 1 | 2021 | 82 | 0.170 |
Why?
|
| Electrons | 1 | 2021 | 51 | 0.170 |
Why?
|
| Radiometry | 1 | 2021 | 61 | 0.170 |
Why?
|
| Mycosis Fungoides | 1 | 2020 | 30 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2021 | 1541 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2022 | 255 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 301 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 401 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2020 | 239 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 422 | 0.150 |
Why?
|
| Cardiology | 1 | 2020 | 134 | 0.140 |
Why?
|
| Bias | 1 | 2019 | 139 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 88 | 0.140 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 193 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2020 | 415 | 0.140 |
Why?
|
| Physician's Role | 1 | 2020 | 186 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2023 | 766 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 327 | 0.130 |
Why?
|
| Kinetics | 1 | 2020 | 1561 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1741 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 517 | 0.130 |
Why?
|
| Serum Albumin, Human | 1 | 2016 | 5 | 0.130 |
Why?
|
| Nomograms | 1 | 2016 | 35 | 0.120 |
Why?
|
| Bilirubin | 1 | 2016 | 134 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 707 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2042 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 621 | 0.110 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 14 | 0.110 |
Why?
|
| Lung | 1 | 2021 | 1380 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 272 | 0.110 |
Why?
|
| Middle Aged | 6 | 2020 | 28299 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 438 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 778 | 0.100 |
Why?
|
| Algorithms | 1 | 2021 | 2018 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1816 | 0.090 |
Why?
|
| Stents | 1 | 2015 | 422 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3922 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 1347 | 0.090 |
Why?
|
| Male | 6 | 2020 | 45792 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2605 | 0.080 |
Why?
|
| Mad2 Proteins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Chromosome Positioning | 1 | 2008 | 4 | 0.070 |
Why?
|
| Metaphase | 1 | 2008 | 21 | 0.070 |
Why?
|
| Anaphase | 1 | 2008 | 20 | 0.070 |
Why?
|
| United States | 1 | 2022 | 7785 | 0.070 |
Why?
|
| Centrosome | 1 | 2008 | 25 | 0.070 |
Why?
|
| Female | 5 | 2020 | 49980 | 0.070 |
Why?
|
| Chromosome Segregation | 1 | 2008 | 35 | 0.070 |
Why?
|
| Catalysis | 1 | 2008 | 216 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2008 | 181 | 0.070 |
Why?
|
| Cytokinesis | 1 | 2008 | 60 | 0.070 |
Why?
|
| cdc25 Phosphatases | 1 | 2007 | 19 | 0.070 |
Why?
|
| Thermodynamics | 1 | 2008 | 329 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 7224 | 0.070 |
Why?
|
| Enzyme Activation | 1 | 2008 | 692 | 0.060 |
Why?
|
| Protein Transport | 1 | 2008 | 439 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 58 | 0.060 |
Why?
|
| Aged | 4 | 2020 | 20927 | 0.060 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2006 | 7 | 0.060 |
Why?
|
| ras Proteins | 1 | 2007 | 134 | 0.060 |
Why?
|
| Fibronectins | 1 | 2006 | 100 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2006 | 95 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2004 | 44 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2004 | 118 | 0.050 |
Why?
|
| Cell Line | 1 | 2008 | 2536 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1810 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 684 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 191 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2015 | 10307 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 204 | 0.040 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 15 | 0.040 |
Why?
|
| Software | 1 | 2023 | 698 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 140 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 71 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 5593 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 325 | 0.040 |
Why?
|
| Adult | 2 | 2016 | 28636 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2021 | 490 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 239 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 1880 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2885 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 905 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1464 | 0.030 |
Why?
|
| S Phase | 2 | 2007 | 64 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1273 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9228 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1982 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2007 | 516 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2860 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2007 | 1642 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4690 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1079 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2928 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1931 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 2776 | 0.020 |
Why?
|
| Mice | 3 | 2007 | 12525 | 0.020 |
Why?
|
| G2 Phase | 1 | 2007 | 33 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1670 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2006 | 25 | 0.020 |
Why?
|
| Lysosomes | 1 | 2006 | 124 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2006 | 198 | 0.010 |
Why?
|
| Receptors, Pituitary Hormone-Regulating Hormone | 1 | 2004 | 2 | 0.010 |
Why?
|
| Receptors, Neuropeptide | 1 | 2004 | 9 | 0.010 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 7 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 463 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2004 | 25 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 58 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2004 | 65 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 67 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 66 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2004 | 33 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2007 | 776 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 279 | 0.010 |
Why?
|
| Transgenes | 1 | 2004 | 186 | 0.010 |
Why?
|
| Estrogens | 1 | 2004 | 202 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 416 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2004 | 342 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 562 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 28901 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1827 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 3483 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 4155 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 2160 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2088 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 1753 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1662 | 0.010 |
Why?
|